News appears to be around the corner on T21. The validation by Dr. Lo will make this stock double.
There are many firms and mutual funds who simply cannot buy at this moment without a validated T21 test. For them it would be a gamble and subject to lawsuits by investors.
Once we have on record a validated T21 test these 15000 mutual fund firms will want to buy in, analysts will then come in with upgrades, shorts will become to cover and, we will break out of a cup and handle position we have been in for a year now, as soon as it breaks $ 8.
The T21 is not priced into the stock since there are a record number of shorts.
This stock reminds me so much of DNDN. In their case they said, "clinical milestone" which everyone understood meant studies succeeded, yet most big firms including SOROS only bought stock in high $ 30 range compared to low $ 3 range when investors knew of results.
There are a large number of buyers whom would rather pay very expensive for know results than, pay very little on what appears to be good news but not yet released.
Professionals do not gamble so, a double is a certainty at this level.